Evaxion A/S (Nasdaq: EVAX) is preparing to unveil new Phase 2 immune biomarker data for EVX-01, its artificial intelligence-designed personalized cancer vaccine being developed for advanced melanoma. The upcoming findings will examine whether the investigational treatment, administered alongside pembrolizumab, produces broader immune system changes beyond the tumor-specific T-cell responses previously documented in patients.
The announcement builds on encouraging Phase 2 results showing a 75% objective response rate at two years, with 12 of 16 patients experiencing measurable tumor responses and four achieving complete responses. More recent three-year follow-up data demonstrated sustained clinical and immune activity, while 89% of the vaccine’s selected neoantigen targets generated tumor-specific immune responses, strengthening interest in the vaccine’s potential as an individualized cancer immunotherapy.
Evaxion will present its expanded biomarker analysis at the Society for Immunotherapy of Cancer Annual Meeting in November. The research could provide important insights into how personalized cancer vaccines influence immune activity over time, although the detailed systemic biomarker findings have not yet been disclosed and EVX-01 remains investigational.
How Evaxion’s EVX-01 Phase 2 melanoma vaccine trial demonstrated sustained clinical and immune responses
EVX-01 is a personalized peptide-based cancer vaccine designed to stimulate immune responses against neoantigens, which are abnormal protein fragments arising from mutations within a patient’s tumor. Because these mutations can differ considerably between individuals, each EVX-01 vaccine is developed according to the molecular characteristics of the patient’s cancer.
The Phase 2 study enrolled 16 patients with advanced melanoma and investigated EVX-01 alongside pembrolizumab, an established immune checkpoint inhibitor marketed as Keytruda by Merck & Co., Inc. Participants received the combination during the first two years, while a subset continued receiving EVX-01 alone during the third year.
At the two-year assessment, the company reported an objective response rate of 75%, representing 12 patients who experienced partial or complete tumor responses. Four participants achieved complete responses, meaning no detectable cancer remained according to the study’s response assessment criteria.
The company also reported that 92% of responding patients maintained their responses at the two-year follow-up. Tumor reduction in target lesions was observed in 15 of the 16 participants, supporting the biological rationale for further investigating the treatment combination.
Subsequent three-year findings provided additional evidence of response durability. Evaxion reported that patients included in the three-year follow-up maintained their previously observed clinical responses without tumor progression during the extended observation period.
These findings are encouraging because maintaining disease control is a major objective in advanced melanoma treatment. However, the study’s small sample size and absence of a randomized comparator limit conclusions about how much benefit can be attributed specifically to EVX-01 rather than pembrolizumab or other patient-related factors.
The continuation of EVX-01 as a stand-alone treatment in a subset of patients provides an additional opportunity to investigate immune persistence after checkpoint inhibitor treatment. Nevertheless, sustained responses during this period cannot independently establish that the vaccine alone maintained disease control.
Larger comparative trials will be required to determine whether adding EVX-01 to pembrolizumab improves clinical outcomes beyond those achievable with existing melanoma treatments.
Why new EVX-01 immune biomarker findings could reveal broader effects of personalized cancer immunotherapy
The latest research focuses on understanding the immunological mechanisms associated with EVX-01 treatment. Evaxion has conducted longitudinal immune profiling to examine how immune responses develop, change and persist during treatment and follow-up.
Earlier analyses concentrated primarily on vaccine-specific T cells capable of recognizing the personalized neoantigens included in EVX-01. The new assessment extends beyond these responses to investigate systemic immune changes associated with administration of the vaccine and pembrolizumab.
Systemic immune modulation refers to changes affecting immune activity more broadly rather than responses restricted to individual vaccine targets. Such findings could provide information about how personalized vaccination influences the wider immune environment during cancer treatment.
This distinction matters because antitumor immunity involves multiple interacting immune-cell populations and signaling mechanisms. A vaccine may generate T cells recognizing selected neoantigens, but successful cancer control also depends on whether those immune cells can reach tumors, remain functional and overcome immunosuppressive conditions.
The upcoming analysis will examine the magnitude, quality, durability and systemic impact of EVX-01-associated immune activity. These measurements could help researchers determine whether the vaccine generates a broader biological response that extends beyond the activation of directly targeted T cells.
Evaxion previously reported that EVX-01 induced immune responses in every patient evaluated, with 89% of selected neoantigen targets generating tumor-specific responses. The findings suggest that its artificial intelligence-based target selection system frequently identifies antigens capable of stimulating measurable immunity.
However, the 89% figure describes the proportion of selected vaccine targets that generated immune responses, not the percentage of patients whose tumors responded. Distinguishing these measures is essential because immunological activity and clinical effectiveness represent different outcomes.
The new data will be presented through an oral session on November 6 and a poster presentation on November 7. Both presentations will examine EVX-01-associated immune responses in patients with advanced melanoma, including biological effects observed during combination treatment.
Until the detailed results are presented, the extent and clinical significance of the reported systemic immune changes remain uncertain. The analysis may strengthen understanding of the vaccine’s mechanism, but it cannot by itself establish additional survival or treatment benefits.
How Evaxion’s AI-Immunology platform designs individualized cancer vaccines targeting melanoma neoantigens
Evaxion develops EVX-01 using its proprietary AI-Immunology platform, which applies computational prediction models to identify tumor-specific neoantigens likely to trigger an immune response.
The process begins with information about an individual patient’s cancer, including tumor-associated mutations and relevant immune characteristics. Computational analysis is then used to select promising neoantigens for inclusion in a personalized peptide vaccine.
This approach differs from conventional vaccines designed around the same antigen for an entire patient population. Instead, EVX-01 is manufactured to target molecular features associated with each patient’s individual tumor.
The therapeutic objective is to train the immune system to recognize malignant cells carrying those neoantigens. Once activated, vaccine-specific T cells may identify and attack cancer cells displaying the corresponding molecular targets.
Combining EVX-01 with pembrolizumab provides a complementary immunotherapy strategy. Pembrolizumab blocks the programmed cell death protein 1 pathway, helping reduce inhibitory signals that can prevent T cells from attacking cancer.
The proposed combination therefore addresses two related aspects of antitumor immunity. EVX-01 is intended to generate targeted T-cell responses, while pembrolizumab helps maintain immune activity by blocking an important checkpoint pathway.
The previously reported 89% neoantigen response rate supports the platform’s ability to identify immunogenic targets within the studied patient population. However, generating a measurable immune response does not guarantee that the targeted cancer cells will be eliminated or that clinical outcomes will improve.
Personalized vaccine development also presents manufacturing and logistical challenges because each treatment must be designed and produced for an individual patient. Production timelines, product quality, scalability and treatment costs will become important considerations if EVX-01 advances into larger clinical studies.
The broader scientific opportunity is substantial because individualized cancer vaccines could potentially address tumor characteristics that are difficult to target through standardized treatment approaches. Nevertheless, their eventual role will depend on demonstrating consistent clinical benefit and practical manufacturing feasibility.
What the latest EVX-01 melanoma findings mean for future clinical development and personalized cancer vaccine research
The forthcoming biomarker presentation represents another milestone in Evaxion’s efforts to establish the scientific foundation of EVX-01. Understanding the relationship between neoantigen-specific T-cell activity, broader immune changes and durable tumor responses could help guide subsequent clinical development.
The company’s three-year follow-up findings provide encouraging observations about sustained responses, but the limited patient population remains an important constraint. Future studies will need to evaluate whether similar outcomes occur across larger and more diverse groups of patients with advanced melanoma.
Another critical question is whether EVX-01 adds measurable benefit to pembrolizumab treatment. Because immune checkpoint inhibitors already demonstrate clinical activity in melanoma, randomized comparisons will be necessary to establish the vaccine’s additional therapeutic contribution.
The research may also help identify biomarkers associated with stronger or more durable responses. Such information could eventually inform patient selection, treatment monitoring and the development of other personalized cancer vaccines.
EVX-01 represents Evaxion’s most advanced clinical-stage asset and an important demonstration of its artificial intelligence-enabled immunotherapy platform. The company is also investigating additional cancer vaccine approaches, including candidates designed to target tumor-associated antigens across broader patient populations.
Its development strategy reflects growing scientific interest in using artificial intelligence to accelerate cancer antigen discovery and improve the precision of immunotherapy design. However, technological sophistication alone does not establish clinical effectiveness, and each vaccine candidate must undergo appropriate safety and efficacy evaluation.
For EVX-01, the immediate priority is establishing a clearer understanding of the immune mechanisms associated with the encouraging Phase 2 observations. The upcoming systemic biomarker findings may provide additional evidence supporting continued development, particularly if they reveal consistent and durable immune changes.
Further evaluation must also address safety, optimal treatment sequencing and the practical requirements of producing individualized vaccines. These considerations will influence whether EVX-01 can eventually progress toward larger clinical trials and potential regulatory review.
The latest announcement underscores the increasing importance of examining both clinical outcomes and immune biomarkers in personalized cancer vaccine research. While tumor responses provide important evidence of treatment activity, detailed immune profiling may explain why certain patients benefit and how those responses are maintained.
Evaxion’s EVX-01 program has demonstrated promising early clinical and immunological findings, including a 75% objective response rate and sustained vaccine-specific T-cell activity. The next challenge is determining whether these observations translate into reproducible improvements over existing melanoma treatment strategies.
Until larger controlled studies establish that benefit, EVX-01 remains an experimental personalized cancer vaccine. Its continued development will depend on confirming the durability, safety and clinical relevance of the immune responses documented in the Phase 2 program.
